Related Experiment Videos
Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose
P M Parikh1, S R Shah, S C Shah
1Sir Hurkisondas Narrotumdas Hospital, Padmashree Gordhanbapa Chowk, Mumbai, India.
Indian Journal of Cancer
|March 1, 1996
Abstract:
Ondansetron was used as an antiemetic along with dexamethasone during 16 cycles of highly or moderately ematogenic chemotherapy. There was major control in two cycles and complete control in the remaining 14. Side effects were minor and did not require discontinuation of the drug. This combination, therefore, appears to be safe and effective in preventing chemotherapy induced emesis.